ShorT spAce or incRease dosage of Biologics for rheumatoid arthritis patients with subclinical synOvitis detected by ultrAsound suppRess joint Destruction

ShorT spAce or incRease dosage of Biologics for rheumatoid arthritis patients with subclinical synOvitis detected by ultrAsound suppRess joint Destruction - STARBOARD study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036601

Enrollment

100

Registered

2019-05-07

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients who fulfill ACR/EULAR criteria and come to see our institution Patients using biologic agents including infliximab, golimumab and tocilizumab

Exclusion criteria

Exclusion criteria: Those who declined enrollment

Design outcomes

Primary

Measure	Time frame
The change in radiographical joint destruction or Power Doppler signal by ultrasound assessment	—

Countries

Japan

Contacts

Public ContactOkano Tadashi

Osaka city university, School of medicine Department of orthopedics

ma1sa3ru@yahoo.co.jp0666453851

Outcome results